2cureX - Individualizing Cancer Treatment

2cureX - Individualizing Cancer Treatment

2cureX A/S is a biotech company with the mission to improve cancer treatment efficiency with the individual patient in focus.

Our innovative scientists at 2cureX have used their exclusive knowledge and experiences to create our core technology - IndiTreat®an easy-to-use in-vitro test specialized in identifying and matching the individual cancer patient with the most effective medical treatment.

In our clinical studies, we have shown that IndiTreat® can identify the right treatment; but more important for individualized cancer therapy is the therapy to which the patient is resistant. With a response rate of only 30% and months to pass before results are measurable using standard treatment regimen, IndiTreat® supports oncologists to find the perfect treatment for each individual patient.

The IndiTreat® test allows medical doctors to test existing chemotherapeutic drugs using a small sample taken from the patient's tumor, which is prepared as tumoroids or micro-tumors and their sensitivity tested for multiple treatment regimens and anti-cancer drug combinations.

2cureX A/S is located at Symbion, Fruebjergvej 3 2100 Copenhagen, Denmark, and 2cureX GmbH is located at the University Medical Center Hamburg-Eppendorf (UKE), one of the largest hospitals in Northern Germany’s and renowned research facility. 2cureX is establishing laboratory facilities for conducting IndiTreat® testing in the UK and other European countries. Furthermore, we have successfully led multiple collaborations with both commercial and academic partners.

2cureX was founded in 2006. The company operates in Biotechnology and Health and wellness industries. Currently, there is no publicly available information about their last investment and investors.